Company
Monte Rosa Therapeutics, Inc. (GLUE)
Standardized SEC financial data for Monte Rosa Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001826457 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-43.8%
Net margin
-31.2%
Revenue growth (YoY)
63.5%
Return on equity
-16.6%
Free cash flow
-$27.5M
Current ratio
6.12×
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $75.6M | $123.7M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $42.9M | $351.4M | $60.2M | $132.7M | $229.1M | $377.1M |
| Total current assets |
Get GLUE data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/GLUE/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/GLUE/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"